PPARγ Antagonist III, G3335 is a cell-permeable dipeptide that acts as a selective and reversible PPAR γ antagonist (KD ~ 8 μM). Shown to inhibit the agonist activity of Rosiglitazone (100 nM) in a dose-dependent manner (IC50 = 31.9 µM) in transfected COS-7 cells.
1. Ye, F., et al. 2006. Chembiochem. 7: 74-82. PMID: 16317783 2. Ho, T.C. et al. 2008. J. Biol. Chem. 283(44): 30273-30288. PMID: 18718914
Soluble in water (30 mg/ml).Addition of a small amount of acid or base may be required for complete solubilization.
Store at 4° C
328.90° C (Predicted)
720.69° C at 760 mmHg (Predicted)
1.43 g/cm3 (Predicted)
n20D 1.66 (Predicted)
α20/D +34.8°, c = 1 in water
agonist activity of Rosiglitazone: IC50 = 31.9 µM
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
Download SDS (MSDS)
Certificate of Analysis
Adobe Acrobat Reader is required to reliably view, print and comment on PDF documents
PPARγ Antagonist III, G3335 (CAS 36099-95-3)
See how others have used PPARγ Antagonist III, G3335 (CAS 36099-95-3). Click on the entry to view the PubMed entry
bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of
HoHo, TC. et al. (PubMed 18718914) used G3335, a dipeptide that acts as a selective PPAR antagonist, to find that p53 protein accumulation and apoptosis induced by 15d-PGJ2 are independent of PPAR activation. -SCBT Publication Review
To place an order using RMB or to ship to mainland China, please visit www.scbio.cn